Articles tagged "Outcome"

2022 American Transplant Congress
Is BK After SPK Okay?: Kidney and Pancreas Transplant Outcomes After BK Viremia
G. Dube¹, K. McCune², D. Cohen³, L. Ratner², S. Husain¹
¹Columbia University Medical Center, New York, NY, ²Columbia University, New York, NY, ³Columbia University Med Ctr, New York, NY
*Purpose: BK viremia and BK nephropathy (BKN) are common after kidney transplant alone, occurring in ~15% and ~1-10%, and are associated with an increased risk…
2022 American Transplant Congress
25 Years of a Standardized Living Donor (LD) Intestinal Transplant Technique – What Has Been Achieved?
R. Gruessner¹, A. C. Gruessner²
¹SUNY Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, MA
*Purpose: The indication for intestinal transplantation (ITX) is irreversible intestinal failure with dependence on total parenteral nutrition (TPN). Most intestinal transplants are from deceased donors…
2022 American Transplant Congress
Increased Costs, Cold Ischemia Time, and Sharing Associated with Removing DSA and OPTN Region from Kidney Allocation: A Single-Center Analysis
R. Forbes¹, A. Dreher¹, E. Zavala², L. A. Hickman¹, L. Smith³, J. Lawson¹, D. Shaffer¹, B. P. Concepcion¹
¹Vanderbilt University Medical Center, Nashville, TN, ²Transplant Center, Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt Transplant Center, Nashville, TN
*Purpose: On March 15, 2021, Donation Service Area (DSA) and OPTN Region were removed from kidney allocation and replaced with a 250 nautical mile (NM)…
2022 American Transplant Congress
Living Donor Robotic Hysterectomy Provides Excellent Outcomes in Uterus Transplant Recipients
L. Johannesson¹, G. J. McKenna¹, A. Wall², J. Bayer¹, G. Testa¹
¹Baylor University Medical Center, Dallas, TX, ²Baylor Scott and White Dallas, Dallas, TX
*Purpose: Living donor (LD) hysterectomy for Uterus Transplantation (UTx) can be performed robotically with vaginal extraction of the graft. There are no reports of the…
2022 American Transplant Congress
The Financial Burden Of Transplant – A Commercial Claims Analysis
G. Katz-Greenberg¹, O. Osazuwa-Peters¹, J. Gonzalez¹, S. Sanoff¹, O. Oloruntoba¹, N. Chan¹, E. J. Gordon², C. Scales¹, A. Brookhart¹, L. McElroy¹
¹Duke University, Durham, NC, ²Surgery, Northwestern University Feinberg School of Medicine, OAK PARK, IL
*Purpose: Despite access to health insurance, financial concerns are among the most prevalent patient-reported barriers to kidney and liver transplantation (KT and LT, respectively). We…
2022 American Transplant Congress
Efficacy and Safety of Delayed, Low-Dose Valganciclovir in High-Risk Cytomegalovirus Liver Transplant Recipients
S. Anders¹, A. Freeman¹, L. Hutchinson¹, U. Kaszubski¹, M. Janusek¹, A. Hooter², D. Raymond², C. Nguyen²
¹Ochsner Medical Center, New Orleans, LA, ²Xavier University, New Orleans, LA
*Purpose: The goal of this study was to compare the safety and efficacy of a delayed valganciclovir (VGCV) dosing protocol for cytomegalovirus (CMV) prophylaxis in…
2022 American Transplant Congress
Single Cell Transcriptomics Reveal Allograft Immune Cell Patterns Associated with Histological Features of Acute Cellular Rejection in Liver Transplantation
L. Tran¹, A. Zahorchak¹, C. Macedo¹, T. Tabib², F. Lakkis³, A. Humar¹, D. Metes¹, A. Thomson¹
¹Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh Medical Center - Thomas E. Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: Development of successful tolerance induction strategies using immune cell-based therapies in transplantation depends on improved understanding of the local intra-graft cellular milieu that underlies…
2022 American Transplant Congress
Are Autoimmune Conditions Disadvantaged Compared to Alcoholic Cirrhosis and Hepatocellular Carcinoma?
S. S. Keeling
Baylor College of Medicine, Houston, TX
*Purpose: Orthotopic liver transplantation (OLT) is a lifesaving therapy for patients with irreversible liver damage caused by autoimmune liver diseases (ALD) including autoimmune hepatitis (AIH),…
2022 American Transplant Congress
Low-Quality Kidney Allograft Use in Kidney Transplantation is Associated with a Prolonged Post-Transplant Length of Stay
J. A. Kahla¹, C. R. Goff¹, J. A. Goss², A. A. Rana²
¹Department of Student Affairs, Baylor College of Medicine, Houston, TX, ²Division of Abdominal Transplantation, Michael E DeBakey Department of General Surgery, Baylor College of Medicine, Houston, TX
*Purpose: The purpose of this study is to determine the effect of low-quality kidney allografts on recipient hospital length of stay following transplant using five…
2022 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV⁺) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study
V. Dharnidharka¹, D. Thirumalai², U. Jaeger³, W. Zhao², D. Dierickx⁴, P. Xun², P. Minga⁵, A. Sawas⁶, N. Sadetsky⁷, P. Chauvet⁸, E. Sundaram⁹, A. Barlev⁷, H. Zimmermann¹⁰, R. U. Trappe¹⁰
¹Washington University School of Medicine/St Louis Children’s Hospital, St Louis, MO, ²Atara Biotherapeutics, Thousand Oaks, CA, ³Medical University of Vienna, Vienna, Austria, ⁴Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁵Niguarda Ca’ Granda Hospital, Milan, Italy, ⁶Herbert Irving Comprehensive Cancer Center, Department of Medicine, CUMC, New York, NY, ⁷Atara Biotherapeutics, South San Francisco, CA, ⁸Service des Maladies du Sang, CHU Lille, Lille, France, ⁹Nashville Biosciences, Nashville, TN, ¹⁰DIAKO Bremen, Bremen, Germany
*Purpose: EBV+ PTLD patients (pts) following SOT who fail rituximab + chemotherapy (CT) have poor outcomes with limited treatment options. Published data on clinical outcomes…